UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
Emerging Prognostic Groups Across the Spectrum of Metastatic Castration-Sensitive Prostate Cancer: Disease Outcomes and Genomics
  • Publication Type:
    Conference presentation
  • Authors:
    Sutera P, Van der Eecken K, Kishan AU, Hamid A, Grist E, Attard G, Lotan TL, Mendes A, Sweeney C, Paller C, Carducci M, Ross AE, Pienta K, Feng FY, Eisenberger M, Antonarakis ES, Ost P, Tran PT, Deek MP
  • Date:
    01/11/2021
  • Status:
    Published
Abstract
PURPOSE/OBJECTIVE(S): Recent evidence has suggested metastatic cancer represents a disease spectrum rather than a binary state and metastasis-directed therapy (MDT) such as radiation may improve outcomes in some individuals with oligometastatic disease. Within metastatic castration-sensitive prostate cancer (mCSPC) several definitions categorize patients into low and high-volume disease. We assess these definitions, association with clinical outcome, and their mutational landscapes. MATERIALS/METHODS: We retrospectively reviewed patients with biochemically recurrent (BCR) or mCSPC who had undergone somatic next-generation sequencing (n = 294). Patients were classified by low and high-volume disease per CHAARTED criteria, STAMPEDE criteria, oligo- or polymetastatic ≤ 3 vs > 3 and ≤ 5 vs > 5 metastases (mets). Kaplan-Meier survival curves were generated for time to development of castrate-resistant prostate cancer (tdCRPC) for each definition and compared using log rank test. Pearson's χ2 of Fischer's exact test determined differences in driver mutations. RESULTS: Patients were classified with four different definitions as follows: CHAARTED low (53.1%) vs high volume (31.3%); STAMPEDE low (49.7%) vs high burden (35.4%); oligometastatic ≤ 3 (47.3%) vs > 3 (37.4%); and, ≤ 5 (54.1%) vs > 5 (30.6%). Median follow-up for the entire cohort was 52.3 months (mos). Median tdCRPC was not reached in patients with BCR; 85.4 vs 17.3 mos for CHAARTED low vs high, respectively; 99.3 vs 15.7 mos for STAMPEDE low vs high, respectively; 101.4 vs 15.7 mos for ≤ 3 vs > 3 mets respectively; and, 86.4 vs 15.4 mos for ≤ 5 vs > 5 mets respectively (P < 0.001 for all definitions). The frequency of mutations in WNT and cell cycle genes increased across the spectrum from BCR to highest volume of disease in all definitions. TP53 mutation frequency increased across the spectrum in the oligometastatic definitions (Table 1). CONCLUSION: The spectrum of mCSPC disease biology is generally confirmed across four different definitions of disease burden for tdCRPC and genomics. For purposes of implementing MDT, a practical approach including an enumeration-centric definition integrated with genomics may be best. Future work will involve examining these various definitions and genomics in de novo and metachronous subsets.
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers
Author
Research Department of Oncology
Author
Research Department of Oncology
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by